Current management and future directions in metastatic pancreatic adenocarcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current management and future directions in metastatic pancreatic adenocarcinoma
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 24, Pages 3765-3775
Publisher
Wiley
Online
2016-09-21
DOI
10.1002/cncr.30342
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
- (2017) Ramesh K. Ramanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
- (2016) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- (2015) Alix Portal et al. BRITISH JOURNAL OF CANCER
- Identification of germline genetic mutations in patients with pancreatic cancer
- (2015) Erin E. Salo-Mullen et al. CANCER
- Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
- (2015) D. Masso-Valles et al. CANCER RESEARCH
- Progress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities
- (2015) Andrew H. Ko JOURNAL OF CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial
- (2015) Aram Hezel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
- (2015) Ehsan Ghorani et al. ONCOLOGY
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Cellular and molecular conspirators in pancreas cancer
- (2014) S. R. Hingorani CARCINOGENESIS
- Stromal reengineering to treat pancreas cancer
- (2014) I. M. Stromnes et al. CARCINOGENESIS
- Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
- (2014) K. H. Yu et al. CLINICAL CANCER RESEARCH
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
- (2013) D. E. Sanford et al. CLINICAL CANCER RESEARCH
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
- (2012) Alberto Zaniboni et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
- (2012) Cindy Neuzillet WORLD JOURNAL OF GASTROENTEROLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
- (2011) M. A. Lowery et al. ONCOLOGIST
- Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma
- (2010) Vittorio Gebbia et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
- (2010) Giuseppe Colucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- (2008) Volker Heinemann et al. BMC CANCER
- Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
- (2008) Seong Yoon Yi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer
- (2008) Carolyn E. Clark et al. CANCER LETTERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started